Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) Net Margin (2016 - 2025)

Historic Net Margin for Regen BioPharma (RGBP) over the last 11 years, with Q3 2025 value amounting to 964.3%.

  • Regen BioPharma's Net Margin fell 8532900.0% to 964.3% in Q3 2025 from the same period last year, while for Dec 2025 it was 427.68%, marking a year-over-year decrease of 806900.0%. This contributed to the annual value of 538.76% for FY2025, which is 2562700.0% down from last year.
  • Per Regen BioPharma's latest filing, its Net Margin stood at 964.3% for Q3 2025, which was down 8532900.0% from 283.23% recorded in Q2 2025.
  • Over the past 5 years, Regen BioPharma's Net Margin peaked at 103772.21% during Q2 2022, and registered a low of 114926.74% during Q1 2022.
  • For the 5-year period, Regen BioPharma's Net Margin averaged around 1187.69%, with its median value being 198.27% (2024).
  • Examining YoY changes over the last 5 years, Regen BioPharma's Net Margin showed a top increase of 1169966200bps in 2022 and a maximum decrease of -1163198000bps in 2022.
  • Quarter analysis of 5 years shows Regen BioPharma's Net Margin stood at 4048.19% in 2021, then crashed by -39bps to 2452.28% in 2022, then plummeted by -110bps to 245.34% in 2023, then crashed by -256bps to 872.57% in 2024, then decreased by -11bps to 964.3% in 2025.
  • Its Net Margin was 964.3% in Q3 2025, compared to 283.23% in Q2 2025 and 32.77% in Q1 2025.